Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Mid Cap ...
Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter for “Longleaf ...
Throughout the last three months, 5 analysts have evaluated Bio-Rad Laboratories (NYSE:BIO), offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...
In a report released on October 28, Brandon Couillard from Jefferies maintained a Buy rating on Bio-Rad Laboratories (BIO - Research Report), with a price target of $600.00. The companys shares closed ...
In a report released today, Conor McNamara from RBC Capital maintained a Buy rating on Bio-Rad Laboratories (BIO – Research Report), with a price target of $401.00. The company’s shares closed ...
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago. These ...
Good day, everyone, and welcome to today's Bio-Rad Second Quarter 2024 Earnings Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. Later, you will have the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results